Compare PVH & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PVH | TWST |
|---|---|---|
| Founded | 1881 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.0B |
| IPO Year | 1994 | 2018 |
| Metric | PVH | TWST |
|---|---|---|
| Price | $65.75 | $48.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 8 |
| Target Price | ★ $91.67 | $48.75 |
| AVG Volume (30 Days) | 734.1K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 0.23% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 3.72 | N/A |
| Revenue | ★ $8,652,900,000.00 | $376,572,000.00 |
| Revenue This Year | $3.64 | $18.89 |
| Revenue Next Year | $1.84 | $15.28 |
| P/E Ratio | $17.78 | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $59.28 | $23.30 |
| 52 Week High | $89.79 | $57.88 |
| Indicator | PVH | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 54.76 |
| Support Level | $61.08 | $25.67 |
| Resistance Level | $72.09 | $57.88 |
| Average True Range (ATR) | 2.03 | 3.06 |
| MACD | -0.37 | -0.68 |
| Stochastic Oscillator | 20.55 | 37.36 |
PVH designs and markets branded apparel in more than 40 countries. Its key fashion categories include men's dress shirts, ties, sportswear, underwear, and jeans. Its two designer brands, Calvin Klein and Tommy Hilfiger, now generate practically all its revenue after its recent disposition of most of its smaller brands. PVH operates e-commerce sites, about 1,400 stores, and about 1,500 shop-in-shops and concessions. The firm also licenses its brands to third parties and distributes its merchandise through department stores and other wholesale accounts. PVH traces its history to 1881 and is based in New York City.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.